Systemic therapy for both squamous cell carcinoma and adenocarcinoma is contingent on performance status, with considerations for testing microsatellites, PD-L1, and human epidermal growth factor receptor 2 (HER2) before initiation, particularly when the respective types of carcinoma are suspected. This evidence concerns the gene ERBB2 and carcinoma.